n-Lorem Publishes Commentary Offering Insight into Potential Commercialization Strategies for Nano-rare Medicines

Lorem publishes commentary titled ‘Establishing a Commercial Solution for Extremely Rare Genetic Diseases’ in Nature Biotechnology.

“CNBC CURES: DEFYING RARE DISEASE” WITH BECKY QUICK TO PREMIERE ON THURSDAY, MARCH 19 AT 7PM ET

"CNBC Cures: Defying Rare Disease" will air on Thursday, March 19 at 7PM ET.

Redefining What's Possible with Gene Editing and ASO Therapies

We are in the golden age of science and technology, advancements in gene editing and ASO therapies are allowing doctors to deliver targeted, and in some cases one-time, interventions for conditions ...
The Pioneer

What is Lorem Ipsum?

Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry's standard dummy text ever since the 1500s, when an unknown printer took a galley of type ...
PR Newswire

n-Lorem and EspeRare announce European collaboration to expand access to individualized ASO Therapies for Rare Genetic Diseases

SAN DIEGO and GENEVA, Jan. 13, 2026 /PRNewswire/ -- The n-Lorem Foundation and the EspeRare Foundation announced today a strategic collaboration to expand access in Europe to n-Lorem's antisense ...
Yahoo Finance

n-Lorem Foundation Celebrates Five Years of Bringing Hope and Potential Treatments to Nano-rare Patients

Five years ago, the n-Lorem Foundation set out on a mission to provide free, lifetime ASO treatments for nano-rare patients. Today, we've made remarkable strides forming a united nano-rare community ...